BioRestorative Therapies Shares Are Trading Higher After the Company Announced FDA Clearance of Its Phase 2 BRTX-100 Clinical Study Protocol Amendment
在生物修复疗法宣布美国食品药品管理局批准其第二阶段 BRTX-100 临床研究协议修正案后,该公司股价走高
BioRestorative Therapies Shares Are Trading Higher After the Company Announced FDA Clearance of Its Phase 2 BRTX-100 Clinical Study Protocol Amendment
在生物修复疗法宣布美国食品药品管理局批准其第二阶段 BRTX-100 临床研究协议修正案后,该公司股价走高
使用浏览器的分享功能,分享给你的好友吧